Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Asia Pacific Breast Implants Market – Insights
Breast implants are medical devices that are used to augment the size of the breasts, either for cosmetic or reconstruction purposes, following mastectomy or to correct a congenital abnormality. The process is called breast augmentation and involves use of breast implants and fat, called as fat transfer breast augmentation, in order to enhance and improve the size of the breasts.
Asia Pacific breast implants market is estimated to account for US$ 329.5 Mn in terms of value by the end of 2027.
Asia Pacific Breast Implants Market: Drivers
Increasing prevalence of breast cancer is expected to propel growth of Asia Pacific breast implants market over the forecast period. For instance, according to the Union Health Ministry, Government of India, 2018 data, the prevalence of breast cancer is 25.8 per 100,000 women and the mortality rate for the disease is 12.7 per 100,000 women. Moreover, around 17, 97,900 women in India may suffer from breast cancer by 2020.
High preference for highly cohesive silicone breast implants is also expected to aid in growth of the market. Silicone breast implants have high strength silicone gel that is textured with silicone shell. Such implants are thicker and contain more cohesive silicone gel, which eliminates the probability of filler leakage into the body.
China held dominant position in Asia Pacific breast implants market in 2019, accounting for 31.4% share in terms of value, followed by Japan.
Figure 1. Asia Pacific Breast Implants Market Share (%), by Region, 2019
Asia Pacific Breast Implants Market: Restraints
Breast implants may lead to rare type of cancers, which is expected to hinder growth of the market. According to the U.S. FDA, breast implants can lead to anaplastic large cell lymphoma, a rare type of fast-growing non-Hodgkin lymphoma.
Moreover, high cost of breast augmentation is also expected to hamper growth of the market. For instance, in India, the total cost of breast augmentation (including cost of implants and cost of surgery) is around US$ 2,800.
Asia Pacific Breast Implants Market: Opportunities
Introduction of lightweight breast implants is expected to offer lucrative growth opportunities for players in the market. Such implants can be developed using cohesive gel filler.
Moreover, use of 3D printing molds in developing prosthetic breasts is also expected to aid in growth of the market. For instance, New Zealand-based myReflection uses 3D scanning and 3D printing molds to develop customized prosthetic breasts for cancer patients who have received a mastectomy.
Silicone Breast Implant segment in Asia Pacific breast implants market was valued at US$ 167.3 Mn in 2019 and is expected to reach US$ 297.0 Mn by 2027 at a CAGR of 7.4% during the forecast period.
Market Trends/Key Takeaways
Saline and silicone implants are the most used of implants in the market. However, teardrop or gummy bear implants are gaining rapid preference, owing to increasing preference for natural looking breasts.
The demand for fat transfer breast augmentation is high in the recent times. This is owing to wide perception among women that individual body fat offers a more natural look and feel; and less invasive nature of the procedure.
Asia Pacific Breast Implants Market: Competitive Landscape
Major players operating in Asia Pacific breast implants market include, Allergan, Plc (Actavis Plc), Mentor Worldwide LLC. (Johnson & Johnson Services, Inc.), GC Aesthetics plc, Sientra, Inc., Groupe Sebbin SAS, Polytech Health & Aesthetics GmbH (Deutsche Beteiligungs AG), Establishment Labs S.A., CollPlant Holdings Ltd., HansBiomed Co., Ltd., Cereplas, and PS Technology Development Limited.
Asia Pacific Breast Implants Market: Key Developments
Major players in the market are focused on approval and launch of products to enhance their market share. For instance, in November 2018, Polytech Health & Aesthetics GmbH received the CE Mark for Polytech and B-Lite breast implants for another five years.
Players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in November 2019, Evonik, a developer of biomaterials for implantable medical devices, partnered with BellaSeno GmbH, a developer of 3D printed absorbable scaffolds, for the use of a RESOMER bioresorbable polymer for an innovative breast implant technology.